China Medical System Holdings Limited announced its unaudited results for the six months ended Jun, 30 2026. Turnover rose 12.5 % year on year to about 837 million Singapore dollars; if all medicines had been sold directly by the group, turnover would have reached roughly 995 million Singapore dollars, up 14.4 %.

Gross profit increased 11.4 % to approximately 600 million Singapore dollars. Profit for the period grew 4.3 % to around 181 million Singapore dollars, while basic earnings per share advanced 4.7 % to RMB 0.4075.

The board declared an interim dividend of RMB 0.1634 per share, equal to about 0.031 Singapore dollars, representing a 5.1 % increase from a year earlier. During the period the company repurchased roughly 6.4 million shares for about 12 million Singapore dollars.

As at Jun, 30 2026 the group held cash and bank balances of roughly 479 million Singapore dollars.

Revenue from innovative and exclusive products climbed 19.7 % to about 316 million Singapore dollars, accounting for 37.7 % of total turnover.

Operational highlights included approval of three innovative drugs in China, five additional innovative drugs under New Drug Application review, three self-developed projects receiving Investigational New Drug approvals, and a new collaboration covering two intravenous iron products. The company’s MSCI ESG rating was raised to AAA during the period.